Logashvari Naidoo
Overview
Explore the profile of Logashvari Naidoo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
638
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Takuva S, Karuna S, Juraska M, Rudnicki E, Edupuganti S, Anderson M, et al.
J Acquir Immune Defic Syndr
. 2021 Dec;
89(4):405-413.
PMID: 34923559
Background: The antibody-mediated prevention (AMP) studies (HVTN 703/HPTN 081 and HVTN 704/HPTN 085) are harmonized phase 2b trials to assess HIV prevention efficacy and safety of intravenous infusion of anti-gp120...
12.
Liu G, Mugo N, Brown E, Mgodi N, Chirenje Z, Marrazzo J, et al.
AIDS
. 2021 Jun;
36(2):257-265.
PMID: 34172672
Objective: Vaccine-preventable human papillomavirus (HPV) infection is common, especially in sub-Saharan Africa where HIV risk is also high. However, unlike other sexually transmitted infections (STIs), HPV's role in HIV acquisition...
13.
Stoner M, Brown E, Palanee-Phillips T, Mansoor L, Tembo T, Nair G, et al.
AIDS Behav
. 2021 May;
25(12):4169-4179.
PMID: 33939034
We analyzed data from 1428 users of the dapivirine vaginal ring, who participated in the MTN-020/ASPIRE phase III trial and subsequent open-label extension MTN-025/HOPE trial, to examine relationships between perceived...
14.
Baeten J, Palanee-Phillips T, Mgodi N, Mayo A, Szydlo D, Ramjee G, et al.
Lancet HIV
. 2021 Feb;
8(2):e87-e95.
PMID: 33539762
Background: Two phase 3 clinical trials showed that use of a monthly vaginal ring containing 25 mg dapivirine was well tolerated and reduced HIV-1 incidence in women by approximately 30%...
15.
Huang Y, Naidoo L, Zhang L, Carpp L, Rudnicki E, Randhawa A, et al.
EBioMedicine
. 2021 Jan;
64:103203.
PMID: 33493795
The phase 2b AMP trials are testing whether the broadly neutralising antibody VRC01 prevents HIV-1 infection in two cohorts: women in sub-Saharan Africa, and men and transgender persons who have...
16.
Peebles K, Kiweewa F, Palanee-Phillips T, Chappell C, Singh D, Bunge K, et al.
Clin Infect Dis
. 2020 Jun;
73(3):513-520.
PMID: 32505132
Background: Limited evidence suggests that the nonhormonal contraceptive copper intrauterine device (Cu-IUD) may increase bacterial vaginosis (BV) risk, possibly due to increased volume and duration of menses, a common side...
17.
Reddy K, Kelly C, Brown E, Jeenarain N, Naidoo L, Siva S, et al.
AIDS
. 2019 Nov;
34(4):559-567.
PMID: 31764068
Objective: We aimed to determine if the dapivirine vaginal ring and the ring device alone (flexible silicone matrix polymer) was associated with the development of cervical cytology abnormalities. Design: Secondary...
18.
Montgomery E, Roberts S, Nel A, Malherbe M, Torjesen K, Bunge K, et al.
AIDS
. 2019 Aug;
33(14):2237-2244.
PMID: 31408030
Objectives: Assessment of safety is an integral part of real-time monitoring in clinical trials. In HIV prevention research, safety of investigational products and trial participation has been expanded to include...
19.
Palanee-Phillips T, Roberts S, Reddy K, Govender V, Naidoo L, Siva S, et al.
J Acquir Immune Defic Syndr
. 2018 Sep;
79(5):580-589.
PMID: 30239426
Background: Long-acting female-initiated methods such as the dapivirine ring may give women greater agency in HIV-1 prevention. However, social harms, defined as nonmedical adverse consequences of study participation or dapivirine...
20.
Balkus J, Brown E, Palanee-Phillips T, Kiweewa F, Mgodi N, Naidoo L, et al.
J Acquir Immune Defic Syndr
. 2017 Sep;
77(1):e8-e10.
PMID: 28961677
No abstract available.